This session examines a real enterprise decision that appeared straightforward and wasn’t.

A global pharmaceutical company was launching a regulated pharmacovigilance platform. The proposed solution was a single vendor model with managed Kubernetes and bundled operations, valued at $6.8M over three years.

The session shows how the discussion moved from opinion to structure. Cost was separated into full versus incremental. Risk was quantified through exit scenarios and audit exposure. Trade-offs were made explicit: one additional month of delivery against long-term control and financial impact.

The outcome did not come from price negotiation. It came from redesigning the decision space and redefining ownership.